Home Companies Catalysts Deep Dives
Ifinatamab deruxtecan I-DXd (DS-7300) PHASE3
Drug Profile
ModalityADC
RouteIV
Therapy AreaOncology
Peak Sales Est$4000M
Formulations[{"id":"idxd-iv-1","route":"IV","setting":"HCP_ONLY","duration":"TBD","frequency":"Every 3 weeks","i
Companies
DSNKY (ORIGINATOR)50%
AZN (CO_DEVELOPER)50%
Mechanism: B7-H3-directed (DXd payload)
Expert: First-in-class B7-H3-directed ADC with DXd payload. B7-H3 is overexpressed in 65% of SCLC and associated with poor prognosis, providing a novel target for this difficult-to-treat cancer.
Everyday: An antibody-drug conjugate that targets B7-H3, a protein found on aggressive cancers including small cell lung cancer and prostate cancer.
Targets: ["B7-H3"]
Programs (3)
IndicationStageKey StudyRegional Status
ES-SCLCPHASE3IDeate-Lung02[]
mCRPCPHASE3IDeate-Prostate01[]
ES-SCLCPHASE3IDeate-Lung02[]
Upcoming Catalysts (1)
I-DXd - SCLC - Ph3 - Clinical Hold Update (IDeate-Lung02) 2026
Notes
First-in-class B7-H3-directed ADC. Phase 3 in SCLC (IDeate-Lung02) and mCRPC (IDeate-Prostate01). 52% ORR in Phase 2 ES-SCLC. Orphan drug designation. Had temporary ILD-related clinical hold (resolved Dec 2025).
Data from Supabase · Updated 2026-03-24